(0.12%) 5 303.27 points
(0.34%) 40 004 points
(-0.07%) 16 686 points
(0.97%) $80.00
(5.73%) $2.64
(1.44%) $2 419.80
(6.36%) $31.78
(2.18%) $1 094.70
(-0.02%) $0.920
(-0.18%) $10.68
(-0.27%) $0.787
(0.19%) $91.05
-2.75% $ 33.10
@ $25.11
Emitido: 14 feb 2024 @ 15:41
Retorno: 31.80%
Señal anterior: feb 13 - 15:43
Señal anterior:
Retorno: 3.95 %
Live Chart Being Loaded With Signals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...
Stats | |
---|---|
Volumen de hoy | 626 199 |
Volumen promedio | 864 498 |
Capitalización de mercado | 2.54B |
EPS | $0 ( 2024-04-25 ) |
Próxima fecha de ganancias | ( $-1.230 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.30 |
ATR14 | $0.0470 (0.14%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-08 | Southwell David P | Sell | 1 650 | Common Stock |
2024-05-07 | Golden Lee Scott | Sell | 175 | Common Stock |
2024-04-19 | Klein Matthew B. | Sell | 3 361 | Common Stock |
2024-04-17 | Pauwels Eric | Sell | 787 | Common Stock |
2024-04-17 | Klein Matthew B. | Sell | 1 307 | Common Stock |
INSIDER POWER |
---|
73.53 |
Last 98 transactions |
Buy: 1 038 941 | Sell: 203 269 |
Volumen Correlación
PTC Therapeutics Inc Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
PTC Therapeutics Inc Correlación - Moneda/Commodity
PTC Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $937.82M |
Beneficio Bruto: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2023 |
Ingresos: | $937.82M |
Beneficio Bruto: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2022 |
Ingresos: | $698.80M |
Beneficio Bruto: | $654.12M (93.61 %) |
EPS: | $-7.79 |
FY | 2021 |
Ingresos: | $538.59M |
Beneficio Bruto: | $506.27M (94.00 %) |
EPS: | $-7.26 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico